Retatrutide side effects: what sulphur burps actually tell you
Quick answer
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials, with Phase 2 data showing significant weight loss alongside frequent GI adverse events including nausea and vomiting (Jastreboff et al., 2023, NEJM). Sulphur burps in this context are consistent with drug-induced delayed gastric emptying, which increases fermentation time for sulphur-containing food compounds. The creator's self-management approach, moderate exercise and steady hydration, has some mechanistic basis, but the drug's contribution to GI vulnerability was not fully acknowledged.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @stanmilsom1 actually say?
Stan woke up with what he called "the eggy burps" after a weekend of eating rich, oily food while on retatrutide. He attributed the sulphur burps to the food rather than purely to the peptide, and said he cleared the symptoms by going for a long walk and sipping water steadily throughout the morning. He also skipped his usual oats, had a small amount of fibre, and took his electrolytes. His conclusion: "things like this happen to everyone" and it's about managing them quickly.
To his credit, he didn't claim retatrutide cured anything, didn't recommend a dose, and framed this as a personal experience rather than medical advice. That restraint matters, and it's rarer than it should be in this corner of TikTok.
Does the science back this up?
Partly, yes. Sulphur burps on GLP-1 receptor agonists and dual/triple agonists like retatrutide are a well-documented side effect tied to delayed gastric emptying, not some mysterious reaction. The mechanism is fairly straightforward, and his remedies have some physiological logic behind them.
Retatrutide acts on GIP, GLP-1, and glucagon receptors simultaneously. Delayed gastric emptying is one of its most consistent gastrointestinal effects, meaning food, including sulphur-containing proteins and fats, sits in the stomach longer and ferments. This produces hydrogen sulphide gas, which is exactly what causes that rotten-egg odour. The Phase 2 trial of retatrutide (Jastreboff et al., 2023, New England Journal of Medicine) reported nausea, vomiting, and GI-related adverse events in a substantial proportion of participants, particularly at higher doses. Walking does accelerate gastric motility. A review by Soffer et al. (1994, Digestive Diseases and Sciences) found that moderate physical activity speeds gastric emptying, which is a real mechanism for why Stan's walk may have helped. Staying hydrated without gulping large volumes is also sensible, since large water boluses can temporarily worsen bloating in people with slowed gastric emptying.
What did they get wrong (or right)?
Stan got more right than wrong here, but he undersells the peptide's role. Blaming the oils and restaurant food entirely isn't the full picture. Retatrutide's gastric slowing means almost any heavy meal carries more GI risk than it would off-drug. The food was a trigger, but the drug set the conditions.
His fix, walking and steady hydration, is genuinely reasonable and has mechanistic support. Skipping his usual oats temporarily was also sensible. High-fibre foods in the context of delayed gastric emptying can worsen bloating and gas production, so reducing fibre acutely during a GI flare is a reasonable short-term strategy, though this isn't a reason to avoid fibre long-term.
What he didn't address is when sulphur burps should prompt more concern. Persistent, severe GI symptoms on any GLP-1-based compound can occasionally signal more serious issues, including gastroparesis rather than simple delayed emptying. If symptoms last more than a day or two, that warrants a clinical conversation, not just a longer walk.
What should you actually know?
Retatrutide is still in clinical trials. It is not approved by the FDA or any major regulatory body as of mid-2025. Anyone using it outside a supervised clinical study is using an investigational compound with an incomplete long-term safety profile. That doesn't mean the side effect management tips here are wrong, but the context matters enormously.
Sulphur burps on triple agonists like retatrutide are common enough that users should plan for them, particularly around meals high in fat, sulphur-rich proteins (eggs, meat, certain vegetables), or alcohol. General strategies that have support in the GI literature include:
- Eating smaller, lower-fat meals, especially in the first weeks of use or after a dose increase.
- Avoiding carbonated drinks, which add gas volume to an already-slowed system.
- Moderate post-meal walking, which has genuine evidence for improving gastric motility.
- Staying hydrated consistently rather than in large amounts at once.
If you are using any investigational peptide or compounded GLP-1-adjacent compound, these GI effects are not just inconvenient. They are signals from your gut that the drug is working as intended, and that your diet needs to adapt around it, not the other way around.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Retatrutide side effects: what sulphur burps actually tell you, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Retatrutide side effects: what sulphur burps actually tell you is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials, with Phase 2 data showing significant weight loss alongside frequent GI adverse events including nausea and vomiting (Jastreboff et al.
FormBlends verdict
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials, with Phase 2 data showing significant weight loss alongside frequent GI adverse events including nausea and vomiting (Jastreboff et al., 2023, NEJM). Sulphur burps in this context are consistent with drug-induced delayed gastric emptying, which increases fermentation time for sulphur-containing food compounds. The creator's self-management approach, moderate exercise and steady hydration, has some mechanistic basis, but the drug's contribution to GI vulnerability was not fully acknowledged.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials, with Phase 2 data showing significant weight loss alongside frequent GI adverse events including nausea and vomiting (Jastreboff et al., 2023, NEJM). Sulphur burps in this context are consistent with drug-induced delayed gastric emptying, which increases fermentation time for sulphur-containing food compounds. The creator's self-management approach, moderate exercise and steady hydration, has some mechanistic basis, but the drug's contribution to GI vulnerability was not fully acknowledged.
- Retatrutide is not FDA-approved as of mid-2025. It is an investigational triple receptor agonist with an incomplete long-term safety profile.
- Phase 2 trial data (Jastreboff et al., 2023, NEJM) reported GI adverse events in a significant proportion of retatrutide users, with nausea being most common and dose-dependent.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Retatrutide is not FDA-approved as of mid-2025. It is an investigational triple receptor agonist with an incomplete long-term safety profile.
- Phase 2 trial data (Jastreboff et al., 2023, NEJM) reported GI adverse events in a significant proportion of retatrutide users, with nausea being most common and dose-dependent.
- Sulphur burps on GLP-1-class drugs are caused by delayed gastric emptying, which increases fermentation time for sulphur-containing foods. The drug creates the vulnerability, the food pulls the trigger.
- Research supports moderate walking as a legitimate gastric motility aid. Soffer et al. (1994, Digestive Diseases and Sciences) found exercise measurably accelerates gastric emptying.
- Sipping fluids rather than gulping them is clinically sensible when gastric emptying is impaired, as large boluses can increase distension and worsen symptoms.
- GI symptoms that persist beyond 24-48 hours on any GLP-1-adjacent compound should prompt clinical review, not just lifestyle adjustments. Severe delayed emptying can escalate to gastroparesis.
- Diet adaptation around these compounds is not optional. Lower-fat meals, smaller portions, and reduced sulphur-rich foods during dose escalation are practical harm-reduction steps with a rationale in the GI literature.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Stan milsom · TikTok creator
62.5K views on this video
This was not fun 🤣 #sulphurburp #peptide #retatrurtide #gymtok #fitness
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Stan milsom, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.